Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program

Novelix Pharmaceuticals Limited has signed a Technology Transfer agreement with GMBU e.V., Germany, marking a strategic collaboration to advance the large-scale production of Astaxanthin, a potent antioxidant with broad nutraceutical and pharmaceutical applications.

Under the agreement, GMBU e.V. will transfer its proprietary technology, expertise, and technical support services for the cultivation and scale-up of Haematococcus pluvialis to Novelix's state-of-the-art laboratories at BTIC Park, Genome Valley, Hyderabad. The collaboration aims to bring Astaxanthin to market at a commercial scale for global supply.

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program, including the provision of algal strains, media components, laboratory equipment, and infrastructure. The company will also establish a GMP-certified production facility at its Techno Park site in Hyderabad to manufacture Astaxanthin in bulk, targeting key markets across Europe, North America, and India.

Dr. Enrico Ehrhardt, Head of the Department of Molecular Biology, GMBU e.V., Germany, commented: "This is a significant milestone for GMBU e.V. as we partner with Novelix Pharmaceuticals Limited, a leading Indian pharmaceutical company, for the development and scale-up of Haematococcus pluvialis. We believe this collaboration will open new avenues for joint innovation across biotechnology and healthcare domains, ensuring affordable access to highquality therapeutic products."

Gattu Gyan Prakash, Director, Novelix Pharmaceuticals Limited, stated: "We are thrilled to collaborate with GMBU e.V., Germany, to bring Astaxanthin production to India. This compound has tremendous therapeutic potential and commercial promise as a nutraceutical. Beyond product development, this partnership symbolizes a robust Indo-German collaboration model in biotechnology and life sciences. Novelix remains committed to advancing transformative, affordable healthcare solutions - from novel drug discovery and medical diagnostics to therapeutics and biomedical devices."